Ligand ID: 032


Drugbank ID:
DB08881
(Vemurafenib)


Indication:
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271]

Get human targets for 032 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '032' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.41A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.79A19.57
None
K1Y  A 404 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.57A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ALA A 129
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.77A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.45A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 296
ILE A 259
ILE A 213
THR A 257
GLY A 215
1.66A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.50A20.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.59A20.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.64A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
PHE A 150
LYS A 102
SER A 113
ASP A 153
1.67A20.78
None
None
DMS  A 402 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m03 MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 283
ALA A 206
ASP A 216
CYH A 300
GLY A 302
1.53A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.61A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.48A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
PHE A 150
LYS A 102
SER A 113
ASP A 153
1.73A20.72
None
None
DMS  A 404 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.57A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		6 / 12
LYS F 356
ILE F 358
SER F 349
PHE F 347
PHE F 342
GLY F 339
1.74A19.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.65A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ILE D  43
SER D  81
HIS D  80
ASP D  56
1.59A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 258
VAL A 212
ALA A 206
CYH A 300
GLY A   2
1.64A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE C 259
ILE C 213
THR C 257
ALA C 260
GLY C 215
1.59A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ILE C  43
SER C  81
HIS C  80
ASP C  56
1.75A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL B 125
ALA B   7
SER D 113
GLY D  11
GLY B  15
1.62A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.52A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE D 259
ILE D 213
THR D 257
ALA D 260
GLY D 215
1.56A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ILE B  43
SER B  81
HIS B  80
ASP B  56
1.66A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ALA A   7
ILE A 152
SER A 139
GLY A 149
PHE A 159
1.80A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE B 259
ILE B 213
THR B 257
ALA B 260
GLY B 215
1.66A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL D 125
ALA D   7
SER B 113
GLY B  11
GLY D  15
1.63A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY C 179
ALA C 173
ILE C 136
THR C 135
GLY C 109
1.56A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY B 258
VAL B 212
ALA B 206
CYH B 300
GLY B   2
1.64A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 125
ALA A   7
SER C 113
GLY C  11
GLY A  15
1.63A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
PHE A   8
PHE C 112
SER A 113
VAL A 125
1.78A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
PHE D   8
PHE B 112
SER D 113
VAL D 125
1.79A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL C 125
ALA C   7
SER A 113
GLY A  11
GLY C  15
1.64A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY D 179
ALA D 173
ILE D 136
THR D 135
GLY D 109
1.58A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
PHE B   8
PHE D 112
SER B 113
VAL B 125
1.77A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY B 179
ALA B 173
ILE B 136
THR B 135
GLY B 109
1.57A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.68A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.77A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.48A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.55A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE C 132
VAL C 134
LEU C 168
TRP C 109
GLY C 165
1.53A18.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.66A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.69A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ALA A 634
LEU A 630
CYH A 697
PHE A 694
GLY A 678
1.71A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6m71 NSP12
(SARS-CoV-2)		6 / 12
VAL A 174
ALA A 176
LEU A 127
LEU A 247
THR A 248
PHE A 165
1.67A14.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 708
SER A 239
SER A 236
GLY A  44
GLY A 712
1.46A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 776
ALA A 771
ILE A 779
ASP A 608
GLY A 616
1.60A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 880
ALA A 866
LEU A 862
SER A 835
GLY A 841
1.46A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 839
ILE A 888
TYR A 884
ALA A 863
GLY A 852
1.60A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ALA A 634
LEU A 630
CYH A 697
PHE A 694
GLY A 678
1.65A14.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6m71 NSP12
(SARS-CoV-2)		4 / 5
ILE A 837
VAL A 880
CYH A 842
HIS A 439
1.66A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 584
LEU B 546
THR B 573
PHE B 543
GLY B 550
1.56A11.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PHE B  43
PHE B 275
SER B  45
VAL B  47
1.65A12.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 587
SER C  46
SER C  45
GLY B 566
PHE B 565
1.31A12.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE C1115
VAL C1104
PHE B1121
HIS C1083
0.98A12.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL C 524
ALA C 522
ALA C 520
PHE C 429
GLY C 431
1.53A12.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL C 976
THR B 572
SER C 746
GLY B 548
PHE B 541
1.56A12.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE B1115
VAL B1104
PHE A1121
HIS B1083
1.17A12.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ALA A 435
ILE A 410
TYR A 508
PHE A 429
GLY A 431
1.30A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PHE C  43
PHE C 275
SER C  45
VAL C  47
1.56A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL B 976
THR A 572
SER B 746
GLY A 548
PHE A 541
1.58A12.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PHE C  43
PHE C 275
SER C  45
VAL C  47
1.43A12.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 4
CYH B 336
PHE B 338
ILE B 332
GLY B 526
1.75A12.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE B1115
VAL B1104
PHE A1121
HIS B1083
1.22A12.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ALA C 435
ILE C 410
TYR C 508
PHE C 429
GLY C 431
1.35A12.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL A   6
ALA A  60
ALA A  55
CYH A 103
GLY A 101
1.41A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLY C 404
VAL C 510
ALA C 419
PHE C 429
GLY C 431
1.54A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
ILE C 410
ILE C 434
ALA C 411
ASP C 428
PHE C 400
1.72A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLY C 404
VAL C 510
ALA C 419
PHE C 429
GLY C 431
1.60A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		6 / 12
GLY H  53
ALA C 435
ILE C 410
TYR C 508
PHE C 429
GLY C 431
1.76A18.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w4b NSP9
(SARS-CoV-2)		5 / 12
ALA B  55
ILE B  92
ILE B  66
THR B  68
PHE B  41
0.98A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w4b NSP9
(SARS-CoV-2)		5 / 12
ALA B  55
ILE B  66
THR B  68
SER B  47
PHE B  41
1.22A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w4h NSP16
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.48A21.65
ACT  A7104 (-4.7A)
None
None
SAM  A7102 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w4h NSP10
NSP16
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.76A22.64
None
None
None
BDF  B4403 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w4h NSP16
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.37A22.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY A6871
VAL A6876
ALA A6881
ASP A6928
GLY A6837
1.76A
SAM  A7104 (-4.4A)
None
None
SAM  A7104 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.56A
EDO  A7102 (-4.8A)
None
None
SAM  A7104 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A6990
ILE A7005
THR A6989
SER A7000
SER A6999
1.73A
None
None
None
KCX  A6935 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6969
LEU A6883
LEU A6848
PHE A7003
GLY A6879
1.66A
None
None
None
None
SAM  A7104 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
ALA A6905
THR A6908
SER B4325
GLY A6871
GLY A6869
1.50A
None
None
None
SAM  A7104 (-4.4A)
SAM  A7104 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w61 NSP10
(SARS-CoV-2)		5 / 12
GLY B4288
ILE B4352
THR B4364
ALA B4277
GLY B4322
1.72A16.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.58A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.53A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.56A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  79
ALA A  38
ILE A 131
ALA A 124
GLY A 133
1.62A
None
AMP  A 201 ( 3.9A)
AMP  A 201 ( 3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w6y NSP3
(SARS-CoV-2)		5 / 12
ALA B 124
LEU B 127
SER B  80
GLY B  97
GLY B 130
1.75A
None
None
None
None
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w6y NSP3
(SARS-CoV-2)		5 / 12
VAL B  49
ALA B 124
LEU B 127
GLY B  97
GLY B 133
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w6y NSP3
(SARS-CoV-2)		5 / 12
VAL A  49
ALA A 124
LEU A 127
GLY A  97
GLY A 133
1.78A
AMP  A 201 ( 3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  79
ALA A  38
ILE A 131
ALA A 124
GLY A 133
1.74A
None
AMP  A 201 ( 3.9A)
AMP  A 201 ( 3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.73A18.00
None
MES  B 201 ( 3.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
ALA A6905
THR A6908
SER B4325
GLY A6871
GLY A6869
1.52A19.50
None
None
None
SAM  A7102 ( 4.2A)
SAM  A7102 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
GLY C6871
VAL C6902
ILE D4291
ASP C6873
PHE B4272
1.51A18.45
SAM  C7105 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w75 NSP10
(SARS-CoV-2)		5 / 12
ILE D4334
VAL D4274
ALA B4276
LEU B4284
GLY B4288
1.50A18.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
(SARS-CoV-2)		5 / 12
VAL D4274
ALA B4276
ALA B4273
ASP D4282
CYH D4332
1.66A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
(SARS-CoV-2)		5 / 12
GLY B4288
ILE B4352
THR B4364
ALA B4277
GLY B4322
1.65A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLY C6911
VAL C7092
ILE A6910
ASP C6900
PHE A6901
1.65A18.45
 NA  C7104 ( 4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP16
(SARS-CoV-2)		4 / 6
PHE C6948
SER C7090
VAL C6916
ASP C6912
1.55A18.45
FMT  C7115 ( 4.3A)
NA  C7104 ( 2.5A)
None
SAM  C7105 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
(SARS-CoV-2)		5 / 12
GLY B4288
ILE B4352
THR B4364
ALA B4277
GLY B4323
1.78A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLY C6879
ALA C6966
ILE C6951
ILE C6969
ASP C6895
1.45A18.45
SAM  C7105 ( 3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
(SARS-CoV-2)		5 / 12
VAL D4274
ALA B4276
ALA B4273
ASP D4282
CYH D4332
1.70A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
GLY A6871
VAL A6902
ILE B4291
ASP A6873
PHE D4272
1.60A18.45
SAM  A7102 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ILE C6969
LEU C6883
LEU C6848
PHE C7003
GLY C6879
1.67A18.73
None
None
None
None
SAM  C7105 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ALA C7056
ILE C7079
THR C7055
GLY C7076
GLY C6963
1.31A19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 5
ILE C6838
VAL C6842
PHE C6901
CYH D4294
1.75A19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ALA A6990
ILE A7005
THR A6989
SER A7000
SER A6999
1.73A19.50
None
None
None
FMT  A7105 ( 2.6A)
FMT  A7104 ( 2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.76A19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ALA C6990
ILE C7005
THR C6989
SER C7000
SER C6999
1.72A19.50
None
None
None
FMT  C7110 ( 2.8A)
FMT  C7108 ( 2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP16
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.44A18.45
None
None
None
SAM  A7102 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLY A6911
VAL A7092
ILE C6910
ASP A6900
PHE C6901
1.53A18.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ILE A6969
LEU A6883
LEU A6848
PHE A7003
GLY A6879
1.71A18.73
None
None
None
None
SAM  A7102 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
ALA C6905
THR C6908
SER D4325
GLY C6871
GLY C6869
1.51A19.50
None
None
None
SAM  C7105 ( 4.2A)
SAM  C7105 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.37A19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ALA A 145
LYS A  92
LEU A  87
THR A  90
GLY A  38
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ALA B 139
LEU B 101
LEU B 117
CYH B 148
GLY B 100
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE B 104
LEU B 120
THR B 119
PHE B 147
PHE B 173
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
GLY B  81
ALA B 149
ILE B 151
ASP B  76
GLY B 163
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ALA B 145
LYS B  92
LEU B  87
THR B  90
GLY B  38
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  81
ALA A 149
ILE A 151
ASP A  76
GLY A 163
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ALA A 149
ILE A 151
TYR A  83
ASP A  76
GLY A 163
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ALA B 145
LYS B  92
LEU B  87
THR B  90
GLY B  38
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE B  14
ALA B 131
LEU B  87
LEU B  80
GLY B  38
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
GLY B 287
ALA B 116
ILE B 151
THR B 168
CYH B 148
1.60A
 CL  B 502 (-3.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 287
ALA A 116
ILE A 151
THR A 168
CYH A 148
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
ALA A  54
ILE A  91
ILE A  65
THR A  67
PHE A  40
1.03A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
ALA A  54
ILE A  65
THR A  67
PHE A  40
GLY A  38
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
ALA A  54
ILE A  65
THR A  67
SER A  46
PHE A  40
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
TYR A  66
ALA A  54
ASP A  26
PHE A  40
GLY A  38
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
ALA A  54
ILE A  91
ILE A  65
THR A  67
ALA A  43
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 12
ALA A  54
ILE A  65
THR A  67
ALA A  43
GLY A  38
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wcf NSP3
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
SER A  80
GLY A  97
GLY A 130
1.73A
None
None
None
None
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 240
ALA A 328
LEU A 330
CYH A 347
GLY A 334
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 240
ALA A 328
LEU A 330
CYH A 347
GLY A 334
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 253
ALA A 328
LEU A 331
GLY A 301
GLY A 337
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wiq NSP8
(SARS-CoV-2)		5 / 12
GLY B 113
ILE B 156
TYR B 149
ALA B 150
GLY B 144
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA C 273
ILE C 292
GLY D 316
PHE C 286
GLY C 287
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA D 308
LEU C 331
ILE D 304
SER D 318
GLY C 321
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA B 273
ILE B 292
GLY A 316
PHE B 286
GLY B 287
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 284
VAL F 270
ALA F 264
THR F 296
ALA E 311
1.56A
None
None
None
None
CL  F 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B 284
VAL B 270
ALA B 264
THR B 296
ALA A 311
1.57A
None
None
None
None
CL  B 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY C 284
VAL C 270
ALA C 264
THR C 296
ALA D 311
1.54A
None
None
None
None
CL  C 401 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B 284
VAL B 270
ALA B 264
THR B 296
ALA A 311
1.56A
None
None
None
None
CL  B 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA F 273
ILE F 292
GLY E 316
PHE F 286
GLY F 287
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B 287
ALA B 308
ILE B 337
ALA A 313
GLY B 335
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA C 313
LYS D 261
ALA D 308
ASP B 297
PHE D 315
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA E 311
ILE F 304
PHE F 274
GLY E 316
GLY F 287
1.61A
 CL  F 401 ( 3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA C 311
ILE D 304
PHE D 274
GLY C 316
GLY D 287
1.59A
 CL  D 401 ( 4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA B 308
LEU A 331
ILE B 304
SER B 318
GLY A 321
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 284
VAL E 270
ALA E 264
THR E 296
ALA F 311
1.58A
None
None
None
None
CL  E 401 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE F 337
LEU E 291
PHE F 314
PHE E 286
GLY E 287
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA D 311
ILE C 304
PHE C 274
GLY D 316
GLY C 287
1.59A
 CL  C 401 ( 3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D 284
VAL D 270
ALA D 264
THR D 296
ALA C 311
1.58A
None
None
None
CL  D 401 ( 4.6A)
CL  D 401 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA A 311
ILE B 304
PHE B 274
GLY A 316
GLY B 287
1.60A
 CL  B 401 ( 3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D 284
VAL D 270
ALA D 264
THR D 296
ALA C 311
1.59A
None
None
None
CL  D 401 ( 4.6A)
CL  D 401 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA A 273
ILE A 292
GLY B 316
PHE A 286
GLY A 287
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY C 287
ALA C 308
ILE C 337
ALA D 313
GLY C 335
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A 284
VAL A 270
ALA A 264
THR A 296
ALA B 311
1.56A
None
None
None
None
CL  A 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA B 311
ILE A 304
PHE A 274
GLY B 316
GLY A 287
1.59A
 CL  A 401 ( 3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 284
VAL F 270
ALA F 264
THR F 296
ALA E 311
1.56A
None
None
None
None
CL  F 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 287
ALA F 308
ILE F 337
ALA E 313
GLY F 335
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 284
VAL E 270
ALA E 264
THR E 296
ALA F 311
1.57A
None
None
None
None
CL  E 401 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A 284
VAL A 270
ALA A 264
THR A 296
ALA B 311
1.57A
None
None
None
None
CL  A 401 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA E 273
ILE E 292
GLY F 316
PHE E 286
GLY E 287
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A 287
ALA A 308
ILE A 337
ALA B 313
GLY A 335
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY C 284
VAL C 270
ALA C 264
THR C 296
ALA D 311
1.53A
None
None
None
None
CL  C 401 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ALA F 311
ILE E 304
PHE E 274
GLY F 316
GLY E 287
1.57A
 CL  E 401 ( 4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6969
LEU A6883
LEU A6848
PHE A7003
GLY A6879
1.73A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
ALA C6905
THR C6908
SER D4325
GLY C6871
GLY C6869
1.51A
None
None
None
SAH  C7102 (-4.4A)
SAH  C7102 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
GLY C6871
VAL C6902
ILE D4291
ASP C6873
PHE B4272
1.57A
SAH  C7102 (-4.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY C6879
ALA C6966
ILE C6951
ILE C6969
ASP C6895
1.44A
SAH  C7102 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY A6879
ALA A6966
ILE A6951
ILE A6969
ASP A6895
1.43A
SAH  A7102 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.45A
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE C6969
LEU C6883
LEU C6848
PHE C7003
GLY C6879
1.71A
None
None
None
None
SAH  C7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 5
ILE C6838
VAL C6842
PHE C6901
CYH D4294
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A6990
ILE A7005
THR A6989
SER A7000
SER A6999
1.75A
None
None
None
FMT  A7104 ( 2.9A)
FMT  A7104 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA C7056
ILE C7079
THR C7055
GLY C7076
GLY C6963
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY A6911
VAL A7092
ILE C6910
ASP A6900
PHE C6901
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wjt NSP10
(SARS-CoV-2)		5 / 12
ILE D4334
VAL D4274
ALA B4276
LEU B4284
GLY B4288
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
VAL C7094
LEU A6893
TRP A6922
SER A6896
GLY B4347
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
ILE A7088
VAL C7094
LEU A6893
TRP A6922
GLY B4347
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA C6990
ILE C7005
THR C6989
SER C7000
SER C6999
1.73A
None
None
None
FMT  C7104 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 6
PHE C6948
SER C7090
VAL C6916
ASP C6912
1.54A
None
FMT  C7107 (-2.7A)
None
SAH  C7102 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
ALA A6905
THR A6908
SER B4325
GLY A6871
GLY A6869
1.50A
None
None
None
SAH  A7102 (-4.4A)
SAH  A7102 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY C6911
VAL C7092
ILE A6910
ASP C6900
PHE A6901
1.65A
FMT  C7107 ( 3.7A)
FMT  C7107 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LYS C 143
ILE C 146
THR C 115
GLY C  85
PHE C 110
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LYS B 143
ILE B 146
THR B 115
GLY B  85
PHE B 110
1.76A
None
MES  B 201 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D  60
ILE A 146
ILE A  84
TYR D 172
GLY A 114
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLY C6911
VAL C7092
ILE A6910
ASP C6900
PHE A6901
1.64A
 NA  C7102 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ALA A6990
ILE A7005
THR A6989
SER A7000
SER A6999
1.73A
None
None
None
FMT  A7106 ( 2.8A)
FMT  A7106 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
ALA C6905
THR C6908
SER D4325
GLY C6871
GLY C6869
1.50A
None
None
None
SFG  C7103 ( 4.1A)
SFG  C7103 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLY A6911
VAL A7092
ILE C6910
ASP A6900
PHE C6901
1.52A
 NA  A7102 ( 4.2A)
NA  A7102 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wkq NSP10
(SARS-CoV-2)		5 / 12
ILE D4334
VAL B4274
LEU B4328
CYH B4332
PHE D4272
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
ALA A6905
THR A6908
SER B4325
GLY A6871
GLY A6869
1.51A
None
None
None
SFG  A7103 ( 4.2A)
SFG  A7103 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP16
(SARS-CoV-2)		4 / 6
PHE C6948
SER C7090
VAL C6916
ASP C6912
1.55A
FMT  C7105 ( 4.4A)
NA  C7102 ( 2.7A)
None
SFG  C7103 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wkq NSP10
(SARS-CoV-2)		5 / 12
ILE D4334
VAL D4274
ALA B4276
LEU B4284
GLY B4288
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP10
(SARS-CoV-2)		5 / 12
VAL D4274
ALA B4276
ALA B4273
ASP D4282
CYH D4332
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ALA C7056
ILE C7079
THR C7055
GLY C7076
GLY C6963
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ILE C6969
LEU C6883
LEU C6848
PHE C7003
GLY C6879
1.69A
None
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ALA C6990
ILE C7005
THR C6989
SER C7000
SER C6999
1.72A
None
None
None
FMT  C7110 ( 3.0A)
FMT  C7110 ( 3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP16
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.43A
None
NA  A7102 ( 3.2A)
None
SFG  A7103 ( 3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLY C6879
ALA C6966
ILE C6951
ILE C6969
ASP C6895
1.44A
SFG  C7103 ( 3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ILE A6969
LEU A6883
LEU A6848
PHE A7003
GLY A6879
1.71A
None
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 5
ILE C6838
VAL C6842
PHE C6901
CYH D4294
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL B   6
ALA B  60
ALA B  55
CYH B 103
GLY B 101
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL A   6
ALA A  60
ALA A  55
CYH A 103
GLY A 101
1.45A
None
None
None
EDO  A 403 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL B   6
ALA B  60
ALA B  55
CYH B 103
GLY B 101
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B  77
VAL B 122
ALA B  81
THR B  84
GLY B 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL A   6
ALA A  60
ALA A  55
CYH A 103
GLY A 101
1.59A
None
None
None
EDO  A 403 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY A  77
VAL A 122
ALA A  81
THR A  84
GLY A 130
1.67A
EDO  A 406 ( 3.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ALA B  95
LEU B  73
ILE B  80
SER B 274
GLY B  77
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B  77
VAL B 122
ALA B  81
THR B  84
GLY B 130
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY A  77
VAL A 122
ALA A  81
THR A  84
GLY A 130
1.61A
EDO  A 406 ( 3.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ALA A  95
LEU A  73
ILE A  80
SER A 274
GLY A  77
1.72A
None
None
None
None
EDO  A 406 ( 3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
PHE A 150
LYS A 102
SER A 113
ASP A 153
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 114
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA C 124
LEU C 127
ILE C  23
SER C  80
GLY C  48
1.78A
None
None
APR  C 201 (-3.9A)
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA D 124
LEU D 127
ILE D  23
SER D  80
GLY D  48
1.74A
None
None
APR  D 201 (-3.8A)
None
APR  D 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
ILE A  23
SER A  80
GLY A  48
1.76A
None
None
APR  A 201 (-4.0A)
None
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.62A
None
APR  B 201 (-3.3A)
APR  B 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL B  49
ALA B 124
LEU B 127
GLY B  97
GLY B 133
1.75A
APR  B 201 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA B 124
LEU B 127
ILE B  23
SER B  80
GLY B  48
1.74A
None
None
APR  B 201 (-3.8A)
None
APR  B 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL D  49
ALA D 124
LEU D 127
GLY D  97
GLY D 133
1.75A
APR  D 201 (-3.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A  49
ALA A 124
LEU A 127
GLY A  97
GLY A 133
1.75A
APR  A 201 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL C  49
ALA C 124
LEU C 127
GLY C  97
GLY C 133
1.73A
APR  C 201 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.59A
None
APR  C 201 (-3.4A)
APR  C 201 (-3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A6990
ILE A7005
THR A6989
SER A7000
SER A6999
1.69A
None
None
None
GTA  A7102 (-2.6A)
GTA  A7102 (-2.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ALA A7056
ILE A7079
THR A7055
GLY A7076
GLY A6963
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY A6879
ALA A6966
ILE A6951
ILE A6969
ASP A6895
1.43A
SAH  A7101 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 6
PHE A6948
SER A7090
VAL A6916
ASP A6912
1.50A
None
None
None
SAH  A7101 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLY A6871
VAL A6876
ALA A6881
ASP A6928
GLY A6837
1.78A
SAH  A7101 (-4.3A)
None
None
SAH  A7101 (-3.7A)
SO4  A7108 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
ALA A6905
THR A6908
SER B4325
GLY A6871
GLY A6869
1.46A
None
None
None
SAH  A7101 (-4.3A)
SAH  A7101 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6969
LEU A6883
LEU A6848
PHE A7003
GLY A6879
1.73A
None
None
None
None
SAH  A7101 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 5
ILE A6838
VAL A6842
PHE A6901
CYH B4294
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wqd NSP8
(SARS-CoV-2)		5 / 12
GLY B 113
ILE B 156
TYR B 149
ALA B 150
GLY B 144
1.71A
None
None
None
EDO  B 302 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wqd NSP8
(SARS-CoV-2)		5 / 12
GLY D 113
ILE D 156
TYR D 149
ALA D 150
GLY D 144
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
ILE A 104
LEU A 120
THR A 119
PHE A 147
PHE A 173
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
ALA A 145
LYS A  92
LEU A  87
THR A  90
GLY A  38
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.63A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PHE B 150
LYS B 102
SER B 113
ASP B 153
1.64A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL B 125
ALA B   7
SER A 113
GLY A  11
GLY B  15
1.58A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.79A19.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE A 200
PHE A 150
HIS A 246
ASP A 295
1.79A19.93
None
None
None
DMS  A 403 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.45A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 296
ILE A 259
ILE A 213
THR A 257
GLY A 215
1.67A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.59A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA A 129
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.77A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
GLY D 113
ILE D 156
TYR D 149
ALA D 150
GLY D 144
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
GLY B 113
ILE B 156
TYR B 149
ALA B 150
GLY B 144
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
GLY B 113
ILE B 156
TYR B 149
ALA B 150
GLY B 144
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
ILE A  91
VAL A  93
LEU A 127
TRP A  68
GLY A 124
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
VAL E 510
ALA E 419
PHE E 429
GLY E 431
1.60A
DMS  E 902 (-3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A 404
VAL A 510
ALA A 419
PHE A 429
GLY A 431
1.56A
DMS  A 903 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
VAL E 510
ALA E 419
PHE E 429
GLY E 431
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.78A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 152
LYS A 100
LEU A  32
THR A  98
PHE A 159
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 114
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
VAL E 510
ALA E 419
PHE E 429
GLY E 431
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A 404
VAL A 510
ALA A 419
PHE A 429
GLY A 431
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 296
ILE A 259
ILE A 213
THR A 257
GLY A 215
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
PHE A 219
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 114
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.56A
None
None
None
None
PEG  A 405 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.76A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE D  18
VAL D 155
ALA D  21
LEU C  88
GLY C  85
1.66A
None
EDO  D 208 ( 4.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.62A
EPE  C 202 (-3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  79
ALA D  38
ILE D 131
ALA D 124
GLY D 133
1.58A
None
EDO  D 205 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL C  49
ALA C 124
LEU C 127
GLY C  97
GLY C 133
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL B  49
ALA B 124
LEU B 127
GLY B  97
GLY B 133
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.73A
EPE  C 202 (-3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.71A
None
APR  C 201 (-3.4A)
APR  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  79
ALA A  38
ILE A 131
ALA A 124
GLY A 133
1.67A
None
APR  A 201 (-3.4A)
APR  A 201 (-3.1A)
None
EDO  A 205 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
ILE A  23
SER A  80
GLY A  48
1.80A
None
None
APR  A 201 (-3.9A)
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL A  49
ALA A 124
LEU A 127
GLY A  97
GLY A 133
1.75A
APR  A 201 (-3.7A)
None
None
None
EDO  A 205 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA D 124
LEU D 127
ILE D  23
SER D  80
GLY D  48
1.78A
None
None
APR  D 201 (-3.9A)
EDO  D 203 (-3.6A)
EDO  D 204 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  79
ALA E  38
ILE E 131
ALA E 124
GLY E 133
1.66A
None
APR  E 201 (-3.3A)
APR  E 201 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL D  49
ALA D 124
LEU D 127
GLY D  97
GLY D 133
1.76A
APR  D 201 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.65A
None
APR  B 201 (-3.4A)
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
SER A  80
GLY A  97
GLY A 130
1.79A
None
None
None
None
APR  A 201 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  79
ALA D  38
ILE D 131
ALA D 124
GLY D 133
1.63A
EDO  D 203 (-3.1A)
APR  D 201 (-3.3A)
APR  D 201 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL E  49
ALA E 124
LEU E 127
GLY E  97
GLY E 133
1.77A
APR  E 201 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.61A
None
APR  C 201 (-3.4A)
APR  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE D  18
VAL D 155
ALA D  21
LEU C  88
GLY C  85
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL B  49
ALA B 124
LEU B 127
GLY B  97
GLY B 133
1.74A
APR  B 201 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA E 124
LEU E 127
ILE E  23
SER E  80
GLY E  48
1.79A
None
None
APR  E 201 (-4.1A)
None
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL C  49
ALA C 124
LEU C 127
GLY C  97
GLY C 133
1.74A
APR  C 201 (-3.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA C 124
LEU C 127
ILE C  23
SER C  80
GLY C  48
1.79A
None
None
APR  C 201 (-3.9A)
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
SER A  80
GLY A  97
GLY A 130
1.77A
None
None
EDO  A 204 (-3.3A)
None
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL C  49
ALA C 124
LEU C 127
GLY C  97
GLY C 133
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA A 124
LEU A 127
SER A  80
GLY A  97
GLY A 130
1.73A
None
None
EDO  A 204 (-3.3A)
None
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL B  49
ALA B 124
LEU B 127
GLY B  97
GLY B 133
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  79
ALA C  38
ILE C 131
ALA C 124
GLY C 133
1.60A
None
MES  C 201 (-3.5A)
MES  C 201 (-4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  79
ALA B  38
ILE B 131
ALA B 124
GLY B 133
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL A  24
ALA A  56
THR A  57
SER B 167
GLY A  51
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL A  24
ALA A  56
THR A  57
SER B 166
GLY A  51
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA C 124
LEU C 127
SER C  80
GLY C  97
GLY C 130
1.78A
None
None
EDO  A 204 ( 4.9A)
None
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA C 124
LEU C 127
SER C  80
GLY C  97
GLY C 130
1.73A
None
None
EDO  A 204 ( 4.9A)
None
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bqy MAIN PROTEASE

(SARS-CoV-2;
synthetic
construct)		5 / 12
GLY A 183
VAL A 186
ALA C   2
THR A 190
ALA A 193
1.63A
None
None
02J  C   1 ( 3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bqy MAIN PROTEASE

(SARS-CoV-2;
synthetic
construct)		5 / 12
GLY A 183
VAL A 186
ALA C   2
THR A 190
ALA A 193
1.62A
None
None
02J  C   1 ( 3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.76A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 708
SER A 239
SER A 236
GLY A  44
GLY A 712
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
ALA A 176
LEU A 127
LEU A 247
THR A 248
PHE A 165
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7btf NSP12
(SARS-CoV-2)		4 / 6
PHE A 422
SER A 425
VAL A 424
ASP A 418
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7btf NSP8
(SARS-CoV-2)		5 / 12
GLY D 113
ILE D 156
TYR D 149
ALA D 150
GLY D 144
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 880
ALA A 866
LEU A 862
SER A 835
GLY A 841
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7btf NSP12
(SARS-CoV-2)		4 / 6
PHE A 422
SER A 434
VAL A 435
ASP A 879
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL A 342
ALA A 379
ILE B 120
ALA A 383
GLY B 113
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
ILE A 757
LEU A 663
LEU A 630
CYH A 697
GLY A 679
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
LEU A 576
THR A 686
GLY A 485
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
NSP7
(SARS-CoV-2)		5 / 12
ALA A 423
LEU A 838
SER C   1
SER C   4
GLY A 839
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
(SARS-CoV-2)		5 / 12
ALA A 634
LEU A 630
CYH A 697
PHE A 694
GLY A 678
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 535
LEU A 351
CYH A 659
PHE A 348
GLY A 352
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7btf NSP12
(SARS-CoV-2)		4 / 5
ILE A 837
VAL A 880
CYH A 842
HIS A 439
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 5
ILE A  43
SER A  81
HIS A  80
ASP A  56
1.63A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ILE A 213
THR A 257
ALA A 260
GLY A 215
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ALA A 129
ILE A 106
ILE A 136
CYH A 160
GLY A 174
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ALA A 211
ILE A 213
SER A 284
GLY A   2
GLY A 302
1.64A
None
None
None
DMS  A 404 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 179
ALA A 173
ILE A 136
THR A 135
GLY A 109
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
PHE A 150
LYS A 102
SER A 113
ASP A 153
1.63A
None
None
DMS  A 406 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv1 NSP12
(SARS-CoV-2)		4 / 5
ILE A 837
VAL A 880
CYH A 842
HIS A 439
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
LEU A 576
THR A 686
GLY A 485
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL A 342
ALA A 379
ILE B 120
ALA A 383
GLY B 113
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
LEU A 576
THR A 686
GLY A 485
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 708
SER A 239
SER A 236
GLY A  44
GLY A 712
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_2
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv1 NSP12
NSP7
(SARS-CoV-2)		4 / 6
PHE A 419
SER C  10
VAL C  11
ASP C   5
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 880
ALA A 866
LEU A 862
SER A 835
GLY A 841
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ALA A 634
LEU A 630
CYH A 697
PHE A 694
GLY A 678
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
ALA A 685
LEU A 576
SER A 759
SER A 692
GLY A 486
1.80A
 A  T  11 ( 4.7A)
None
U  P  20 ( 2.8A)
None
ZN  A1002 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_A_032A801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv2 NSP12
(SARS-CoV-2)		4 / 5
ILE A 837
VAL A 880
CYH A 842
HIS A 439
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 880
ALA A 866
LEU A 862
SER A 835
GLY A 841
1.38A
None
None
U  P  17 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
ALA A 634
LEU A 630
CYH A 697
PHE A 694
GLY A 678
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 174
ALA A 176
LEU A 127
LEU A 247
THR A 248
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
VAL A 662
THR A 686
ALA A 634
PHE A 571
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
ALA A 176
LEU A 127
LEU A 247
THR A 248
PHE A 165
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
ILE A 757
LEU A 663
LEU A 630
CYH A 697
GLY A 679
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL A 342
ALA A 379
ILE B 120
ALA A 383
GLY B 113
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OG7_A_032A1_1
(AKAP9-BRAF FUSION
PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
LEU A 576
THR A 686
GLY A 485
1.70A
None